Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025198 | 1.00 | TSHR (0.41) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL23735868 | 0.84 | — | — | |
| SCHEMBL2836682 | 0.82 | TSHR (0.38) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL16351759 | 0.82 | TSHR (0.38) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL2836684 | 0.82 | TSHR (0.38) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL20326265 | 0.81 | ALDH1A1 (0.31) | TSHR | |
| Hydrochloric Acid SCHEMBL3391031 | 0.80 | GABRR1 (0.37) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL30381032 | 0.79 | CHRM2 (0.47) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL20326378 | 0.79 | CHRNB2 (0.30) | — | |
| SCHEMBL2842621 | 0.77 | PIK3CD (0.38) | TSHRGABRR1GABRR2BLMGABRR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | claimed |
| EP-2516403-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | Imperial Innovations Limited (GB) | 2012-10-31 | — | — | EP | claimed |
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516403-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | Imperial Innovations Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077095-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116206-A1 | QUINOLINE DERIVATIVES USED AS PET IMAGING AGENTS | ERBB2, EGFR, ERBB4 | TSHR 122/4885GABRR1 2346/4885GABRR2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.